Changes in capacity to consent over time in patients involved in psychiatric research

Barton W. Palmer, Gauri N. Savla, Scott C. Roesch and Dilip V. Jeste

Background
Informed consent is a key element of ethical clinical research. Patients with serious mental illness may be at risk for impaired consent capacity. Corrective feedback improves within-session comprehension of consent-relevant information, but little is known about the trajectory of patients’ comprehension after the initial enrolment session.

Aims
To examine whether within-session gains in understanding after feedback were maintained between study visits and to examine stability of decisional capacity over time.

Method
This was a longitudinal, within-participants comparison of decisional capacity assessed at baseline, 1 week, 3 months, 12 months and 24 months in 161 people with schizophrenia or bipolar disorder.

Results
Within-session gains from corrective feedback generally dissipated over each follow-up interval. Decisional capacity showed a general pattern of stability, but there was significant between-participant heterogeneity. Better neuropsychological performance was associated with better decisional capacity across time points. Positive symptoms of schizophrenia did not predict any aspects of decisional capacity, but general psychopathology, negative symptoms and depression evidenced some modest associations with certain subdomains of decisional capacity.

Conclusions
Informed consent may be most effectively construed as an ongoing dialogue with participants at each study visit.

Declaration of interest
None.

‘Informed consent is a process, not just a form,’ although often heard, in the actual practice of clinical trials is this statement merely an empty platitude? How should it be actualised in longitudinal research? These questions are of particular importance in clinical trials for psychotic disorders which, by their very nature, may be associated with fluctuations in mental coherence. Moreover, disease-related variables, such as medication adjustment or withdrawal may acutely exacerbate symptoms and impair mental status. Mental status fluctuations, in turn, may adversely affect a person’s capacity to monitor whether continued participation is in his or her best interest.

The European Clinical Trials Directive (Directive 2001/20/E), as well as US consent regulations, focus on consent capacity at the time of enrolment. However, as explicitly acknowledged in section 34 of the Mental Capacity Act 2005 for England and Wales, in some longitudinal studies, a participant may lose capacity to consent prior to the conclusion of the project. Furthermore, researchers have an ethical duty to ensure that participants are giving competent voluntary consent throughout study participation. The Public Policy Platform from the US National Alliance on Mental Illness asserts that ‘Research participants should be carefully evaluated before and throughout the research for their capacity to comprehend information and their capacity to consent to continued participation in the research.’ Conversely, other relevant stakeholders suggest that uniform assessment of decision-making capacity, even at the point of initial enrolment, may be unnecessary and potentially exacerbate stigma associated with mental illness. Guidelines regarding this matter would ideally be informed by empirical data. There is now a sizable empirical literature on informed consent among patients with schizophrenia spectrum disorders, but these studies have been almost exclusively focused on the time of initial study enrolment.

Among participants in the schizophrenia arm of the Clinical Antipsychotic Trials in Intervention Effectiveness study, Stroup et al found 24% evidenced >1 standard deviation decline and 20% a >1 standard deviation improvement on the understanding subscale of the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) over a 6- to 18-month follow-up. Better baseline cognitive function predicted longitudinal improvement, and worsening of symptoms predicted declines in decisional capacity. These findings illustrate that fluctuating decisional capacity occurs in a non-trivial proportion of participants in psychiatric clinical trials. But the term ‘decisional capacity’ refers to a patient’s potential to understand (as well as appreciate, reason with and express a choice about) the relevant information. The construct overlaps with, but is not fully synonymous with, that of a manifest level of performance on measures of decisional capacity, which is constrained by one’s capacity, but also by contextual factors, including the quality of the consent process. Capacity, as a trait, might be less malleable; manifest comprehension can be readily enhanced by optimising the consent/disclosure process.

Cross-sectional studies demonstrate that a simple process using questions to assess understanding and then providing corrective feedback can improve participants’ within-session comprehension of consent-relevant information. The dearth of longitudinal studies makes it difficult to assess whether information is then effectively retained. Nonetheless, given the ease with which iterative questioning and re-explanation can be incorporated into standard consent procedures, it is worth considering if such methods lead to durable changes in manifest comprehension. In the present study of 161 patients with schizophrenia or bipolar disorder, we examined whether within-session gains in understanding made through corrective feedback were maintained over time, as well as examining the factors associated with change in level of decisional capacity over a follow-up period of up to 24 months. We hypothesised that there would be significant retention of gains in understanding information across visits. We also examined potential predictors of within-individual changes in understanding, appreciation and reasoning over time, including diagnostic category, age, education, severity of psychopathology and cognitive functioning.
Method

Study design
This was a longitudinal within-participants comparison of decisional capacity assessed at baseline, 1 week, 3 months, 12 months and 24 months. As described below, in addition to assessing decisional capacity at these time points, severity of psychiatric symptoms and neurocognitive dysfunction were also assessed at all but the 1-week visit.

Participants
The participants in this study were 132 community-dwelling out-patients with schizophrenia and 29 with bipolar disorder considering participation in a study of the short- and long-term side-effects of antipsychotic medications among middle-aged and older patients (131 of whom enrolled in the host study). Some participants provided baseline decisional capacity data for prior reports, however, the present report is the first investigation of the longitudinal data. We limited analyses to participants with a DSM-IV-TR diagnosis of schizophrenia or bipolar disorder. For inclusion in the present analyses all participants were required to have contributed decisional capacity data for at least two of the five time points; 161 participants met this criterion (20 additional patients for whom we had only baseline data were excluded from the present analyses); 137 participants completed at least three visits, 92 completed at least four visits and 52 completed all five visits. (In some instances participants missed an earlier visit but then returned for a later visit. For example, 20 missed the 1-week visit but then completed the 3-month visit.) Diagnoses were established by participants’ mental healthcare providers. This protocol was reviewed and approved by the University of California, San Diego Human Research Protections Program, and all participants provided written informed consent to participate in this study.

The host study was a longitudinal investigation of the side-effects of Food and Drug Administration-approved antipsychotic medications among middle-aged and older patients. Procedures for the host study were generally non-invasive, involving clinical interviews, psychopathology ratings, brief cognitive testing and evaluations for motor side-effects (such as tardive dyskinesia) that were repeated at regular intervals for periods of up to 2–5 years. The host study was itself minimal risk in that none of the evaluations was painful or dangerous, there was no placebo control, and participants were permitted to stay on their current medications as managed by their clinical provider.

Measures
Sociodemographic information regarding each participant’s age, education, gender, ethnic background and medication status was collected through interview or review of available records.

Manifest comprehension and capacity to consent to research
Manifest comprehension and capacity to consent to research was evaluated with the MacArthur Treatment Competence Assessment Tool for Clinical Research (MacCAT-CR). This 15–20 min, semi-structured interview provides subscale scores for four dimensions of decision-making capacity: understanding (range 0–26), appreciation (range 0–6), reasoning (range 0–8) and expression of a choice (range 0–2). Higher scores indicate better performance. As per standard MacCAT-CR procedures, information relevant to answering the items was tailored to a specific protocol (the host study described above). The disclosure of study-related information was presented verbally and was embedded as part of the MacCAT-CR interview. (Formal consent for the host study, including review of the associated informed consent form, was conducted after completion of the baseline decisional capacity evaluation with those participants who expressed an interest in such participation during the MacCAT-CR interview.) As the construct of decision-making capacity refers to one’s potential for comprehending disclosed information, rather than merely one’s memory for information, standard MacCAT-CR procedures make provisions for correcting any initially misunderstood information. Specifically, information that is initially misunderstood is re-explained and retested. We scored the understanding subscale three times – Trial 1: reflecting the person’s response after the initial disclosure; Trial 2: after re-explanation of any poorly understood information; Trial 3: after a second re-explanation of any lingering areas of suboptimal understanding. The same procedure was employed during follow-up evaluations at 1 week, 3 months, 12 months and 24 months.

Severity of psychopathology
Severity of psychopathology was measured at all the visits except the 1-week visit, with the positive, negative and general symptom subscales of the Positive and Negative Syndrome Scale (PANSS), and with a four-item PANSS mania factor. In addition, severity of depressive symptoms was evaluated with the 17-item version of the Hamilton Rating Scale for Depression (HRSD).

Neuropsychological functioning
Neuropsychological functioning was assessed with the following neurocognitive test battery (repeated at all but the 1-week visit): Arithmetic, Digit Span, Letter-Number Sequencing, Digit Symbol, and Symbol Search subtests from the Wechsler Adult Intelligence Scale (WAIS–III); Trail Making Test Parts A and B, Hopkins Verbal Learning Test – Revised (free recall total), Story Memory Test (learning), Brief Visuospatial Memory Test – Revised (free recall total), Family Pictures subtest from the Wechsler Memory Scale – Third Edition (immediate recall), Wisconsin Card Sorting Test 64-version (conceptual level responses), Stroop Test (Interference Trial, number completed). At the baseline evaluation the participants completed additional neuropsychological tests that were not included in the present analyses (see Palmer & Jeste); the above subset of tests was selected to focus on cognitive abilities that were thought most likely to fluctuate during the course of the study. Each test score was coded such that higher scores indicated better performance; scores were then transformed to a z-score scale using the normalised rank function in SPSS 19.0 for Windows. We then calculated a composite mean z-score at each visit, which we used as the neurocognitive variable in our statistical analyses.

Statistical analyses
Paired t-tests comparing MacCAT-CR understanding scores at Trial 3 to Trial 1, within each session, were conducted to examine the degree to which understanding of disclosed material improved with re-explanation. In addition, paired t-tests comparing the MacCAT-CR Trial 1 scores at each follow-up visit to the baseline Trial 3 scores were conducted to evaluate the degree to which the within-session gains were lost by the follow-up visit. Hierarchical linear modelling (HLM) was used to examine the trajectory of the decisional capacity subscale scores, i.e. understanding (Trials 1 and 2), appreciation and reasoning across at least two and up to five repeated assessments. The Trial 3 scores
were excluded from the HLM as they were expected to have a more constricted range than those for Trial 1 and Trial 2. (Inclusion of Trial 3 scores also would have inflated the number of parallel analyses.) Trial 2 scores correspond to ‘decisional capacity’ as operationalised under standard MacCAT-CR procedures.13 We examined baseline (i.e. intercept) and longitudinal (i.e. slope) performances of the MacCAT-CR subscales at both the individual participant and group levels. The hypothesis that people with schizophrenia or bipolar disorder would show stable performance on all components of the MacCAT-CR was evaluated in terms of the slope of the unconditional growth model, because this parameter reflects the increase, decrease or stable pattern of scores across time of the entire sample. We conducted follow-up examinations of predictors when the variances around the intercept and slope were significant. Model testing proceeded in three phases: (a) unconditional model (to calculate intraclass correlation coefficients (ICCs)), (b) unconditional growth model with time (in weeks) as a predictor and (c) conditional growth models (intercepts and slopes as outcomes model) with both baseline (diagnostic category, age and education level) and longitudinal (HRSD, PANSS subscale scores and neurocognitive composite z-score) predictors. (The HRSD, PANSS and neurocognitive tests were not administered at the 1-week visit.) All regression coefficients presented in the results section are unstandardised $b$. Significance was $P<0.05$ (two-tailed) for all analyses.

Results

Sociodemographic and clinical characteristics of the sample

Relative to the participants with schizophrenia, those with bipolar disorder were slightly older (mean age 52.5 years (s.d. = 6.9) and 55.7 (s.d. = 10.7), respectively, $t(159) = 2.04$, $P = 0.043$), and were more educated (mean years completed 12.3 (s.d. = 2.2) and 13.4 (s.d. = 2.1) respectively, $t(159) = 2.32$, $P = 0.022$). There were no other significant group differences in sociodemographic or clinical characteristics (Table 1). (This was an out-patient/community-dwelling sample, and participants were generally clinically stable at the times of assessment.)

Persistence or dissipation over study visits of within-session gains in understanding from repeated explanation

The distribution of the understanding scores across trials at each study visit is depicted in Fig. 1. The overall pattern was one of within-session improvement when initially misunderstood information was re-explained, but with a dissipation of improvement (‘re-spreading’ of scores) at each subsequent follow-up assessment. At the baseline visit the mean understanding score at Trial 3 was 6.5 (s.d. = 4.0) points higher than the Trial 1 score (17.3 (s.d. = 5.5) v. 23.8 (s.d. = 4.0) respectively, $t(159) = 20.7$, $P<0.001$). The parallel within-session gain from Trial 1 to Trial 3 was similar at each subsequent visit (online Table DS1). Comparing Trial 1 scores at each follow-up to the baseline Trial 3 scores provides an index of the degree to which within-visit gains were subsequently lost between visits. The mean Trial 1 score at the 1-week follow-up was 4.4 points lower than the mean baseline Trial 3 score, $t(139) = 12.7$, $P<0.001$. Similarly, the Trial 1 scores at the 3-month, 12-month, and 24-month follow-ups were 4.8, 5.1, and 4.9 points below the baseline Trial 3 score respectively (all three $t$s > 7.80, all three $P$-values < 0.001).

Stability and trajectory of scores

Between-individual variance, reflected by the ICCs from the unconditional model of the understanding Trials 1 and 2, and reasoning scores were not predictive of any MacCAT-CR components (Table DS2). Diagnostic status was a significant predictor of appreciation ($b = 0.45$, $P = 0.010$) and reasoning ($b = 0.40$, $P = 0.022$) over time. The regression coefficients related to neuropsychological ability were positive and significant predictors of performance on all four components of the MacCAT-CR (understanding Trial 1 $b = 3.61$, $t = 2.45$; reasoning $b = 0.43$; appreciating $b = 0.34$; all four $P$-values < 0.001). That is, better neuropsychological performance was associated with better scores on the MacCAT-CR regardless of time point. Negative symptom scores were negatively and significantly associated with the understanding Trial 1 performance over time ($b = 0.15$, $P = 0.030$), so that worse negative symptoms (higher scores) were predictive of poorer performance. Negative symptoms were not significantly predictive of the other components of the MacCAT-CR (online Table DS2). Positive symptoms were not predictive of any MacCAT-CR components (online Table DS2), but general psychopathology and depression were both significantly related to appreciation ($b = 0.04$ and 0.04, respectively, $P$-values < 0.044).

Table 1 Baseline demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Age, years: mean (s.d.)</th>
<th>52.5 (6.9)</th>
<th>55.7 (10.4)</th>
<th>2.04</th>
<th>159</th>
<th>0.043</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education, years: mean (s.d.)</td>
<td>12.3 (2.2)</td>
<td>13.4 (2.1)</td>
<td>2.32</td>
<td>159</td>
<td>0.022</td>
</tr>
<tr>
<td>Gender, women: n (%)</td>
<td>55 (41.7)</td>
<td>14 (48.2)</td>
<td>0.42</td>
<td>1</td>
<td>0.515</td>
</tr>
<tr>
<td>Ethnicity, White: n (%)</td>
<td>76 (57.6)</td>
<td>21 (72.4)</td>
<td>2.19</td>
<td>1</td>
<td>0.139</td>
</tr>
<tr>
<td>Depression (17-item Hamilton Rating Scale for Depression, total) mean (s.d.)</td>
<td>8.9 (6.1)</td>
<td>10.7 (5.3)</td>
<td>1.48</td>
<td>155</td>
<td>0.141</td>
</tr>
<tr>
<td>Positive and Negative Syndrome Scale (PANSS), mean (s.d.)</td>
<td>14.4 (6.3)</td>
<td>12.8 (4.8)</td>
<td>1.26</td>
<td>158</td>
<td>0.211</td>
</tr>
<tr>
<td>Negative symptom score (PANSS negative total)</td>
<td>13.2 (5.0)</td>
<td>13.4 (4.9)</td>
<td>0.17</td>
<td>158</td>
<td>0.867</td>
</tr>
<tr>
<td>General psychopathology (PANSS general, total)</td>
<td>27.1 (7.3)</td>
<td>28.0 (7.2)</td>
<td>0.65</td>
<td>158</td>
<td>0.519</td>
</tr>
<tr>
<td>Mania (PANSS mania index)</td>
<td>5.6 (2.4)</td>
<td>5.8 (2.2)</td>
<td>0.33</td>
<td>158</td>
<td>0.740</td>
</tr>
<tr>
<td>Composite neuropsychological z-score, mean (s.d.)</td>
<td>−0.05 (.70)</td>
<td>−0.05 (.64)</td>
<td>0.017</td>
<td>153</td>
<td>0.987</td>
</tr>
</tbody>
</table>
or unpleasant side-effects that might occur. But the amount of
visit in the context of the larger study goals, as well as any adverse
understands the purpose and procedures of that particular study
beginning of each study visit, ensuring that the participant
participants.35) But brief, simple language disclosures, provided
as a method of managing institutional risk, rather than as a means
printed consent form. (As noted in a report from the Institute
recommendation need not entail a formal reiteration of the
focused on the time of initial enrolment.4–6 But the present
per se
dissipation of improvement at each subsequent follow-up
within-session improvement of comprehension, but with a
maintained over time. The overall observed pattern was one of
feedback during consent for a psychiatric research trial are
This is the first large-scale study to examine the degree to which
within-session gains in comprehension achieved with corrective
feedback during consent for a psychiatric research trial are
manifested in decisional capacity over time. There were slight improvements in
MacCAT-CR performance over study visits, but the magnitude of
these practice effects was relatively small. However, there was also
significant between-individual heterogeneity in the slopes of
decisional capacity scores over time, suggesting there may be
a subset of patients for whom fluctuation in consent-related
skills may indeed be a relevant concern. Neuropsychological
performance was associated with better scores on the MacCAT-CR
regardless of time point. When dealing with patients whose cognitive
abilities may change, clinical trials researchers should be alert to
possible changes in the participant’s ability to give meaningful
ongoing consent for participation.

Limitations
Schizophrenia diagnosis (rather than bipolar disorder) appeared
to be associated with greater fluctuation in some aspects of
manifest performance or decisional capacity; however,
interpretation of the latter finding is limited given the relatively
 euthymic level of affective symptoms in our sample. That is,
among people with severe acute manic symptoms, and/or severe
depressive symptoms, greater fluctuation than presently observed
might reasonably be expected in both manifest performance and
decisional capacity (see Misra et al36). Furthermore, in the
case of consent for a procedurally complex trial, or one with
a complex risk–benefit profile, retention of information and/or
overall stability of decisional capacity may be different from the
pattern observed in the present study. Such distinctions may be
of particular importance when the issue is not just whether the
level of manifest comprehension has changed, but whether some
threshold for capable/incapable status has been crossed (see
Stroup et al12). With regard to the need to avoid singling out or
unduly stigmatising those with severe mental illness, it should also
be noted that our sample was restricted to patients with
schizophrenia and bipolar disorder. It is quite possible that the
pattern of dissipation in understanding seen between study visits
would be present in non-psychiatric research participants as well.

Implications
The above limitations notwithstanding, the present findings have
two important implications for how informed consent is
conducted in the context of longitudinal research: (a) informed
consent discussions need to be interactive and integrated
throughout the clinical trial process, not merely at the time of
enrolment, and (b) some, but not all, patients experience
fluctuations in decisional capacity. If a participant is at risk for
not being able to monitor and evaluate whether continued
participation remains in his/her best interest, for example because
of an exacerbation of cognitive dysfunction, then periodic
reassessment of that decisional capacity may be warranted. (There
were also some isolated findings with regard to severity of
symptoms and decisional capacity, but those for neurocognitive
performance were stronger and more consistent at least within this
relatively stable community-dwelling sample.) When a participant
loses capacity for consent, this need not entail automatic
withdrawal from the study. Some jurisdictions allow research to
continue with assent from the participant and consent from a
legally authorised representative. Indeed, even if a participant loses

Discussion

Main findings
This is the first large-scale study to examine the degree to which
within-session gains in comprehension achieved with corrective
feedback during consent for a psychiatric research trial are
maintained over time. The overall observed pattern was one of
within-session improvement of comprehension, but with a
dissipation of improvement at each subsequent follow-up
assessment. This dissipation does not appear to be a change in
decisional capacity per se as the overall pattern of scores between
study visits for was one of general stability.

Current regulations regarding the research consent process are
focused on the time of initial enrolment.1–6 But the present
findings illustrate the importance of incorporating an interactive
informed consent discussion into every study visit. This
recommendation need not entail a formal reiteration of the
printed consent form. (As noted in a report from the Institute of
Medicine, printed consent forms seem to have been ‘hijacked’
as a method of managing institutional risk, rather than as a means
for optimising communication of key information to research
participants.)35) But brief, simple language disclosures, provided
in a systematic format with a natural comprehensible
conversational tone, along with brief evaluation of participants’
comprehension, can be readily incorporated with minimal added
burden (see Palmer et al35). This might be as simple as, at the
beginning of each study visit, ensuring that the participant
understands the purpose and procedures of that particular study
visit in the context of the larger study goals, as well as any adverse
or unpleasant side-effects that might occur. But the amount of
detail reviewed, and the degree to which such procedures are
themselves standardised and become a focus of formal institutional
review board oversight, should depend on factors such as the
vulnerability of the study population to cognitive impairment, as
well as the risks associated with study participation.

The current findings indicate an overall pattern of stability in
decisional capacity over time. There were slight improvements in
MacCAT-CR performance over study visits, but the magnitude of
these practice effects was relatively small. However, there was also
significant between-individual heterogeneity in the slopes of
decisional capacity scores over time, suggesting there may be
a subset of patients for whom fluctuation in consent-related
skills may indeed be a relevant concern. Neuropsychological
performance was associated with better scores on the MacCAT-CR
regardless of time point. When dealing with patients whose cognitive
abilities may change, clinical trials researchers should be alert to
possible changes in the participant’s ability to give meaningful
ongoing consent for participation.
capacity for consent to research, he or she may still retain capacity to appoint a proxy for decision-making.37 Another possible approach is the use of a research advance directive in which participants are asked to indicate their preferences, a priori, in the event they lose capacity to consent.38 The specific solution will, of course, depend on the provisions recognised in the applicable legal jurisdiction but knowing the factors associated with fluctuating capacity to consent can be helpful in making appropriate contingency plans.

Barton W. Palmer, PhD, University of California, San Diego, Department of Psychiatry, La Jolla, Veterans Medical Research Foundation, San Diego and Stein Institute for Research on Aging, La Jolla, California; Gauri N. Savla, PhD, University of California, San Diego, Department of Psychiatry, La Jolla, California; Scott C. Roesch, PhD, San Diego State University, Department of Psychology, San Diego, California; Dilip V. Jeste, MD, University of California, San Diego, Department of Psychiatry and Stein Institute for Research on Aging, La Jolla, California, USA.

Correspondence: Barton W. Palmer, University of California, San Diego MC 0993, 9500 Gilman Drive, La Jolla CA 92093-0993, USA. Email: bpalmer@ucsd.edu

First received 17 Sep 2012, final revision 4 Jan 2013, accepted 18 Feb 2013

Funding

This work was supported, in part, by NIH grants MH64722, T32MH019934, 5P30MH066248, and the Department of Veterans Affairs.

References


3 Appelbaum PS. Decisional capacity of patients with schizophrenia to consent to research: taking stock. Schizophr Bull 2006; 32: 22–5.


20 Palmer BW, Jeste DV. Relationship of individual cognitive abilities to specific components of decisional capacity among middle-aged and older patients with schizophrenia. Schizophr Bull 2006; 32: 98–106.


458
Table DS1  Within-session improvements in MacCAT-CR Understanding scores.

<table>
<thead>
<tr>
<th>Study Visit</th>
<th>Trial 1</th>
<th>Trial 3</th>
<th>t</th>
<th>df</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>17.3 (5.5)</td>
<td>23.8 (4.0)</td>
<td>20.7</td>
<td>159</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>1-week</td>
<td>19.4 (5.3)</td>
<td>24.3 (3.2)</td>
<td>14.8</td>
<td>140</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3-months</td>
<td>18.9 (5.1)</td>
<td>24.2 (3.7)</td>
<td>18.4</td>
<td>137</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>1-year</td>
<td>18.8 (5.3)</td>
<td>24.5 (3.0)</td>
<td>15.2</td>
<td>99</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>2-years</td>
<td>18.8 (5.2)</td>
<td>24.6 (3.1)</td>
<td>11.1</td>
<td>60</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Table DS2  Baseline and longitudinal predictors of the components of the MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR)

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Components of the MacCAT-CR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Understanding (Trial 1)</td>
</tr>
<tr>
<td>Time (weeks)</td>
<td>.013 (.04),</td>
</tr>
<tr>
<td></td>
<td>p = .014</td>
</tr>
<tr>
<td>Age*</td>
<td>.06 (.04),</td>
</tr>
<tr>
<td></td>
<td>p = .104</td>
</tr>
<tr>
<td>Education*</td>
<td>.07 (.13),</td>
</tr>
<tr>
<td></td>
<td>p = .594</td>
</tr>
<tr>
<td>Diagnostic Status (SC v. BPD)*</td>
<td>.44 (.78),</td>
</tr>
<tr>
<td></td>
<td>p = .571</td>
</tr>
<tr>
<td>Composite neuropsychological performance</td>
<td>3.61 (.39),</td>
</tr>
<tr>
<td></td>
<td>p &lt; .001</td>
</tr>
<tr>
<td>PANSS positive symptom scores</td>
<td>.01 (.07),</td>
</tr>
<tr>
<td></td>
<td>p = .859</td>
</tr>
<tr>
<td>PANSS negative symptom scores</td>
<td>-.15 (.070),</td>
</tr>
<tr>
<td></td>
<td>p = .030</td>
</tr>
<tr>
<td>PANSS general psychopathology scores</td>
<td>-.06 (.07),</td>
</tr>
<tr>
<td></td>
<td>p = .413</td>
</tr>
<tr>
<td>HAM-D depressive symptom scores</td>
<td>.10 (.06),</td>
</tr>
<tr>
<td></td>
<td>p = .114</td>
</tr>
</tbody>
</table>

b = unstandardized regression coefficients
SE = robust standard errors
*baseline predictors, rest are longitudinal predictors
SC = schizophrenia; BPD = bipolar disorder ; PANSS = Positive and Negative Syndrome Scale; HRSD = 17-item Hamilton Rating Scale for Depression.
Changes in capacity to consent over time in patients involved in psychiatric research
Barton W. Palmer, Gauri N. Savla, Scott C. Roesch and Dilip V. Jeste
Access the most recent version at DOI: 10.1192/bjp.bp.112.121160

Supplementary Material
Supplementary material can be found at:
http://bjp.rcpsych.org/content/suppl/2013/05/03/bjp.bp.112.121160.DC1

References
This article cites 19 articles, 4 of which you can access for free at:
http://bjp.rcpsych.org/content/202/6/454#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;202/6/454

Downloaded from http://bjp.rcpsych.org/ on June 26, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/